<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="63369" id="root" date="1996-09-19" xml:lang="en">
<title>USA: FDA panel backs Teva's Copaxone drug.</title>
<headline>FDA panel backs Teva's Copaxone drug.</headline>
<dateline>GAITHERSBURG, Md. 1996-09-19</dateline>
<text>
<p>A Food and Drug Administration advisory committee unanaimously recommended on Thursday that the agency approve Israel's Teva Pharmaceutical Industries Ltd's Copaxone drug for treating Multiple Sclerosis.</p>
<p>After a nearly all-day hearing, the FDA advisory panel concluded that the drug is safe and effective when used to reduce exacerbations of the disease.  </p>
<p>The panel's recommendations are not binding but the regulatory agency typically follows the advice of its advisory committees.</p>
<p>The panel's support for Teva's Copaxone clears a major hurdle for the company as it expands its focus to research-based drugs. It has been known as a leading generic drug company. FDA panel members expressed some concerns about the absence of carcinogenic studies and about such reported side effects as chest pain. But none of those concerns were enough to keep any of the panel members from recommending the drug be approved by the FDA.  </p>
<p>If the FDA ultimately approves the drug, the Copaxone label would be limited to a claim of reducing exacerbation of the disease.</p>
<p>Some 250,000 to 350,000 people in the United States, the vast majority of which are young women, suffer from the central nervous system disease. There are no cures for the disease, which results in patients slowly losing control of their movement, speech and bodily functions.</p>
<p>While two other FDA-approved MS treatments are already on the market, the Copaxone drug takes a different approach toward mitigating the disease.</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="ISRAEL">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C13">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
  <code code="C21">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
  <code code="GCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
  <code code="GHEA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-19"/>
  </code>
</codes>
<dc element="dc.date.created" value="1996-09-19"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1996-09-19"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="GAITHERSBURG, Md."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
